Ad is loading...
EQNUX
Price
$22.48
Change
-$0.15 (-0.66%)
Updated
Nov 15 closing price
RMFCX
Price
$58.23
Change
-$0.50 (-0.85%)
Updated
Nov 15 closing price
Ad is loading...

EQNUX vs RMFCX

Header iconEQNUX vs RMFCX Comparison
Open Charts EQNUX vs RMFCXBanner chart's image
MFS Equity Income R4
Price$22.48
Change-$0.15 (-0.66%)
VolumeN/A
CapitalizationN/A
American Funds American Mutual R3
Price$58.23
Change-$0.50 (-0.85%)
VolumeN/A
CapitalizationN/A
EQNUX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
EQNUX vs. RMFCX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EQNUX is a StrongBuy and RMFCX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 104B vs. EQNUX (602M). EQNUX (1.77) and RMFCX (1.69) have matching dividends . EQNUX was incepted earlier than RMFCX: EQNUX (12 years) vs RMFCX (22 years). EQNUX is a more actively managed with annual turnover of: 42.00 vs. RMFCX (25.00). EQNUX has a lower initial minimum investment than RMFCX: EQNUX (0) vs RMFCX (250). EQNUX (22.18) and RMFCX (21.31) have marching annual gain over last year. EQNUX return over 5 years is better than : 55.53 vs. RMFCX (44.92).
EQNUXRMFCXEQNUX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence12 years22 years-
Gain YTD15.57816.44095%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets602M104B1%
Annual Yield % from dividends1.771.69105%
Returns for 1 year22.1821.31104%
Returns for 3 years11.5515.4675%
Returns for 5 years55.5344.92124%
Returns for 10 years104.1765.01160%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MNTS0.630.01
+1.10%
Momentus
WWW21.79-0.24
-1.09%
Wolverine World Wide
SNAP10.60-0.16
-1.49%
Snap
SHC14.31-0.68
-4.54%
Sotera Health Company
ENTA9.53-0.60
-5.92%
Enanta Pharmaceuticals